Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial
Information source: Kyushu University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Combination pill of losartan and hydrochlorothiazide (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Kyushu University Official(s) and/or principal investigator(s):
Kiyoshi Matsumura, MD PhD, Principal Investigator, Affiliation: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Summary
The purpose of the study is to determine whether combination pill of losartan potassium and
hydrochlorothiazide will improve medication compliance among patients with high blood
pressure.
Clinical Details
Official title: A Randomized Trial to Establish the Effects of Combination Pill of Losartan Potassium and Hydrochlorothiazide on Medication Compliance Among Patients With High Blood Pressure.
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Medication compliance
Secondary outcome: Blood pressurecost of blood pressure lowering drugs serious adverse events adverse events blood test
Detailed description:
Despite clear evidence that blood pressure lowering treatment is beneficial for reduction of
cardiovascular disease, blood pressure levels are not adequately controlled in many
hypertensive patients. More intensive blood pressure lowering treatment is required to
achieve maximum reduction of cardiovascular disease. Combination pills of blood pressure
lowering drugs could be a safe and effective strategy to achieve blood pressure target but
there is no randomized evidence that established the beneficial effects of combination pills
of blood pressure lowering drugs. The purpose of the study is to determine whether
combination pill of losartan potassium and hydrochlorothiazide will improve medication
compliance among patients with high blood pressure.
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Aged 20 years or above
- Hypertension defined as blood pressure levels of >/=140/90mmHg or current use of
blood pressure lowering drugs
- Able to commence combination therapy of angiotensin receptor antagonists and
diuretics
Exclusion Criteria:
- Blood pressure measurements of >/=200/120mmHg
- Previous serious adverse events due to angiotensin receptor antagonists or diuretics
- Known or possible pregnancy
- Known severe liver dysfunction
- Known severe kidney disease
- Known contraindication to angiotensin receptor antagonists or diuretics
- Taking >/=4 tablets except for angiotensin receptor antagonists
- ACE inhibitors, thiazide or thiazide-like diuretics in the morning
- Current participation in another clinical trial
- A high likelihood that the patient is not suitable for the study treatment
Locations and Contacts
Department of Medicine and Clinical Science, Kyushu University, Fukuoka City, Fukuoka 812-8582, Japan
Additional Information
Starting date: June 2008
Last updated: March 4, 2011
|
